SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research,...
Hence then, the article about hanchorbio and wuxi biologics enter strategic partnership to advance next generation bi and multi functional fusion protein pipeline was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline )
Also on site :
- Hackers Pose as Microsoft Support to Breach Corporate Defenses .. PYMNTS.com
- The devil wears Old Navy? Inside Hollywood’s favorite movie marketing blitz
- How a Spanish startup pivoted to video AI and built a $230 million ARR business with no VC funding